Skip to content

ENSYSCE BIOSCIENCES, INC.: 10-Q filed 2021-06-08

What ENSYSCE BIOSCIENCES, INC. reported in its quarterly report filed 2021-06-08 (fiscal Q1 2021): 20 published measures, 39 facts as tagged in accession 0001493152-21-013768.

This filing

Form
10-Q (quarterly report)
Filed
2021-06-08
Fiscal period
fiscal Q1 2021
Accession
0001493152-21-013768 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENSYSCE BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-03-3112,980,390USD
At 2020-12-3112,854,634USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-03-3111,086,555USD
At 2020-12-3114,061,692USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-03-311,893,835USD
At 2020-12-31-1,207,058USD
At 2020-03-314,517,562USD
At 2019-12-315,000,001USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-1,711,607USD90
2020-01-01 to 2020-03-311,792,718USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-266,168USD90
2020-01-01 to 2020-03-31-234,388USD91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-03-31297,500USD90
2020-01-01 to 2020-03-31-135,283,492USD91

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-62,500USD90
2020-01-01 to 2020-03-31134,624,680USD91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-03-31-2,919,287USD
At 2020-12-31-1,207,680USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-61,278USD90
2020-01-01 to 2020-03-3174,625USD91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-292,027USD90
2020-01-01 to 2020-03-31-915,183USD91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-03-31228,213USD
At 2020-12-31226,464USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-01-01 to 2020-03-3131,428USD91

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-03-31319,180USD
At 2020-12-31260,404USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2020-03-30 to 2020-03-31136,283,492USD2
2020-01-01 to 2020-03-31136,283,492USD91

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-01-01 to 2021-03-31292,027USD90
2020-01-01 to 2020-03-31915,183USD91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-03-316,224,268shares
At 2020-12-316,224,268shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-03-314,812,500USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-1,772,885USD90
2020-01-01 to 2020-03-311,867,343USD91

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-1,480,858USD90
2020-01-01 to 2020-03-312,782,526USD91

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-61,278USD90

Inspect the source

Entity
ENSYSCE BIOSCIENCES, INC. / CIK 0001716947
Captured
2026-09-21T17:24:39.335Z
SEC response SHA-256
28573a09f81da1511239531464c03b2552a3554a684a233653f365b194b6ca0b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001716947.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))